Optimal vancomycin serum level in Staphylococcus aureus infections

被引:16
作者
Bingen, E.
Mariani-Kurkdjian, P.
Nebbad, B.
机构
[1] Hop Robert Debre, APHP, Microbiol Serv, F-75935 Paris 19, France
[2] Hop Dupuytren, Microbiol Serv, F-91210 Draveil, France
来源
MEDECINE ET MALADIES INFECTIEUSES | 2006年 / 36卷 / 09期
关键词
through serum level; MIC; staphylococcus; vancomycin;
D O I
10.1016/j.medmal.2006.07.016
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Vancomycin is the cornerstone of therapy against methicillin-resistant Staphylococus aureus in both community and nosocomial-acquired infections. Because vancomycin is a concentration-independent or time-dependant antibiotic, most clinicians have abandoned the routine practice of determining peak serum concentrations to rely solely on monitoring serum concentrations. The so-called therapeutic range most often quoted for vancomycin was assessed for through serum concentrations of 5-10 mg/l. But prolonged exposure to serum concentration close to the MIC is associated with the emergence of resistance. More recent guidelines recommended vancomycin in concentrations of 15-20 mg/l for the treatment of severe Staphylococcus infections or in situations where vancomycin penetration is poor. However, because of the great variability of vancomycin MICS (0,12-4 mg/l) of susceptible Staphylococcus strains, guidelines should recommend through serum concentrations of 5-10 times the MIC. (c) 2006 Elsevier Masson SAS. Tons droits reserves.
引用
收藏
页码:439 / 442
页数:4
相关论文
共 37 条
  • [1] [Anonymous], ANTIMICROB AGENTS CH
  • [2] [Anonymous], REANIMATION
  • [3] Carbon C, 1990, Scand J Infect Dis Suppl, V74, P163
  • [4] Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus
    Charles, PGP
    Ward, PB
    Johnson, PDR
    Howden, BP
    Grayson, ML
    [J]. CLINICAL INFECTIOUS DISEASES, 2004, 38 (03) : 448 - 451
  • [5] Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
    Craig, WA
    [J]. CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) : 1 - 10
  • [6] CURTIS GG, 2006, J ANTIMICROB CHEMOTH, V57, P589
  • [7] Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy
    Drew, RH
    Perfect, JR
    Srinath, L
    Kurkimilis, E
    Dowzicky, M
    Talbot, GH
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (05) : 775 - 784
  • [8] Elting LS, 1998, CANCER, V83, P2597, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2597::AID-CNCR27>3.0.CO
  • [9] 2-L
  • [10] Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001
    Fridkin, SK
    Hageman, J
    McDougal, LK
    Mohammed, J
    Jarvis, WR
    Perl, TM
    Tenover, FC
    [J]. CLINICAL INFECTIOUS DISEASES, 2003, 36 (04) : 429 - 439